The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma
Jordan Gauthier, MD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, covers the data for JCAR021, bearing a human CD19-binding single chain variable fragment, for relapsed/refractory acute lymphoblastic leukemia (ALL) and B-cell lymphoma (NCT03103971). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
